Genelux Corp (GNLX)

Currency in USD
3.340
-0.250(-6.96%)
Closed·
After Hours
3.570+0.230(+6.89%)
·
GNLX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Earnings results expected in 0 days
GNLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.3103.610
52 wk Range
1.9305.885
Key Statistics
Prev. Close
3.34
Open
3.61
Day's Range
3.31-3.61
52 wk Range
1.93-5.885
Volume
79.14K
Average Volume (3m)
149.66K
1-Year Change
73.06%
Book Value / Share
0.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GNLX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.000
Upside
+438.92%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Genelux Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Genelux Corp Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Compare GNLX to Peers and Sector

Metrics to compare
GNLX
Peers
Sector
Relationship
P/E Ratio
−4.2x−3.1x−0.5x
PEG Ratio
−0.450.010.00
Price/Book
4.2x2.7x2.6x
Price / LTM Sales
-241.2x3.3x
Upside (Analyst Target)
343.8%106.0%43.4%
Fair Value Upside
Unlock3.3%7.1%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.000
(+438.92% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.20 / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GNLX Income Statement

People Also Watch

17.96
SRPT
+10.46%
37.39
EXEL
-0.85%
1.840
OTLK
-2.13%
1.850
IPA
-2.12%
2.920
MBOT
+1.74%

FAQ

What Stock Exchange Does Genelux Trade On?

Genelux is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Genelux?

The stock symbol for Genelux is "GNLX."

What Is the Genelux Market Cap?

As of today, Genelux market cap is 124.67M.

What Is Genelux's Earnings Per Share (TTM)?

The Genelux EPS (TTM) is -0.88.

When Is the Next Genelux Earnings Date?

Genelux will release its next earnings report on 18 Aug 2025.

From a Technical Analysis Perspective, Is GNLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Genelux Stock Split?

Genelux has split 0 times.

How Many Employees Does Genelux Have?

Genelux has 24 employees.

What is the current trading status of Genelux (GNLX)?

As of 08 Aug 2025, Genelux (GNLX) is trading at a price of 3.34, with a previous close of 3.34. The stock has fluctuated within a day range of 3.31 to 3.61, while its 52-week range spans from 1.93 to 5.89.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.